



MEDIA ADVISORY

Merrimack to Present Preclinical and Phase 1 Data at the 33rd Annual San Antonio Breast Cancer Symposium

MM-111 first-in-human phase 1/ 2 and pharmacologic study in patients with advanced refractory HER2-Positive (HER2+) cancers

MM-302 pre-clinical safety and activity study of anthracycline delivery to HER2-Positive (HER2+) tumors

CAMBRIDGE, MA, December 8, 2010 – Merrimack Pharmaceuticals, Inc. announced today that it will present MM-111 Phase 1 clinical data at the 33rd Annual San Antonio Breast Cancer Symposium, as well as pre-clinical data on MM-302, a HER2+ tumor anthracycline delivery study.

MM-111

A poster will show data on MM-111, a bi-specific antibody that targets tumor cells over-expressing ErbB2/HER2. MM-111 is designed to inhibit the signaling between ErbB2/HER2 and ErbB3/HER3 thus disabling the phosphatidylinositol 3-kinase (PI3K) pathway and preventing tumor proliferation.

Poster P6-15-15 shows clinical data from a first-in-human Phase 1/ 2 study evaluating the safety and tolerability of MM-111 in HER2+ advanced breast cancer.

Title: A Phase 1/ 2 and pharmacologic study of MM-111 in patients with advanced, refractory HER2-Positive (HER2+) Cancers

Poster Session: 6

Number: P6-15-15

Date/Time: Sunday, December 12 from 7:00 - 8:30 am

Location: Exhibit Hall C in the category "Treatment - Therapeutic Strategies: Novel Targets and Targeted Agents."

MM-302

A poster will show pre-clinical data on MM-302, a HER2-targeted liposomal doxorubicin. MM-302 is designed to have significant advantages over both free and liposomal doxorubicin by targeting higher levels of doxorubicin to HER2-expressing tumor cells.

Poster P3-14-09 shows pre-clinical data on MM-302's safety and activity as an anthracycline delivery vehicle to HER2+ tumors.

Title: Pre-clinical safety and activity of MM-302, a HER2-targeted liposomal doxorubicin designed to have an improved safety and efficacy profile over approved anthracyclines

Poster Session: 3

Number: P3-14-09

Date/Time: Friday, December 10, 5:30-7:30 pm

Location: Exhibit Hall A-B in the category "Treatment - Therapeutic Strategies: HER2-Targeted Therapy"

About Merrimack

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer. The Company is advancing a robust pipeline of engineered therapeutics paired with molecular diagnostics. In addition to several pre-clinical and research stage programs, Merrimack has three oncology candidates in clinical development: MM-121 in Phase 2 clinical testing in partnership with sanofi-aventis, MM-111 in Phase 1/2 clinical testing, and MM-398, in Phase 2 clinical testing in partnership with PharmaEngine, Inc. MM-121, MM-111, and MM-398 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The Company's proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, integrates the fields of engineering, biology and computing to enable mechanism-based model driven discovery and development of both therapeutics and diagnostics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit <http://www.merrimackpharma.com>.

Contact: Kathleen Petrozzelli, Corporate Communications, Merrimack, 617-441-1043
Betsy Stevenson, RaymondStevenson Healthcare Communications, 860-984-1424

#